Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs. simultaneous ceftazidime-avibactam + aztreonam infusion for MBL-producing carbapenem-resistant Gram-negative infections
ChiCTR2600120543Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ceftazidime + avibactam and aztreonam in Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 3 more (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Plasma drug concentrations and Microbial culture and antimicrobial susceptibility test results. Started Mar 2026; status: recruiting.
02
Drugs
ceftazidime + avibactamaztreonam
03
Conditions
Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)bloodstream infection (BSI)
Beyond the preview
Go deeper on ChiCTR2600120543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120543.